Can serum be used for analyzing the KRAS mutation status in patients with advanced colorectal cancer?

Seung Tae Kim, Won Jin Chang, Lihua Jin, Jae Sook Sung, Yoon Ji Choi, Yeul Hong Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose KRAS mutations have been used widely as prognostic or predictive marker in patients with advanced colorectal cancer (CRC). However, it may be difficult to obtain a tumor tissue for analyzing the status of KRAS mutation in large proportion of patients with advanced disease. Materials and Methods We obtained pairs of tumor and serum samples from 65 patients with advanced CRC, between March 2008 and July 2011. KRAS mutation status from the tumor samples was analyzed by genomic polymerase chain reaction and direct sequence, and KRASmutation status from the serum samples was determined by a genomic polymerase chain reaction- restriction fragment length polymorphism assay. Results KRAS mutations were detected in the serum samples of 26 patients and in the tumor samples of 31 patients. KRAS mutation status in the serum and tumor samples was consistent in 44 of the 65 pairs (67.7%). There was a significant correlation between the mutations detected in the serum sample and the mutations detected in the matched tumor sample (correlation index, 0.35; p <0.004). Twenty-two of the 57 patients (38.5%) received anti-epidermal growth factor receptor therapy as any line therapy. There was no significant difference in the overall survival (OS) in accordance to the status of KRASmutations in both the serum and tumor samples (p > 0.05). In a multivariate analysis, liver metastasis and no cytoreductive operation were independent prognostic factors for decreased OS. Conclusion The serum sample might alternatively be used when it is difficult to obtain tumor tissues for analyzing the status of KRAS mutation in patients with advanced CRC.

Original languageEnglish
Pages (from-to)796-803
Number of pages8
JournalCancer Research and Treatment
Volume47
Issue number4
DOIs
Publication statusPublished - 2015

Fingerprint

Colorectal Neoplasms
Mutation
Serum
Neoplasms
Polymerase Chain Reaction
Restriction Fragment Length Polymorphisms
Multivariate Analysis
Neoplasm Metastasis
Liver

Keywords

  • KRAS
  • Mutation
  • Neoplasms
  • Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Can serum be used for analyzing the KRAS mutation status in patients with advanced colorectal cancer? / Kim, Seung Tae; Chang, Won Jin; Jin, Lihua; Sung, Jae Sook; Choi, Yoon Ji; Kim, Yeul Hong.

In: Cancer Research and Treatment, Vol. 47, No. 4, 2015, p. 796-803.

Research output: Contribution to journalArticle

@article{7f73e0f0073046db93433bd13f789ff7,
title = "Can serum be used for analyzing the KRAS mutation status in patients with advanced colorectal cancer?",
abstract = "Purpose KRAS mutations have been used widely as prognostic or predictive marker in patients with advanced colorectal cancer (CRC). However, it may be difficult to obtain a tumor tissue for analyzing the status of KRAS mutation in large proportion of patients with advanced disease. Materials and Methods We obtained pairs of tumor and serum samples from 65 patients with advanced CRC, between March 2008 and July 2011. KRAS mutation status from the tumor samples was analyzed by genomic polymerase chain reaction and direct sequence, and KRASmutation status from the serum samples was determined by a genomic polymerase chain reaction- restriction fragment length polymorphism assay. Results KRAS mutations were detected in the serum samples of 26 patients and in the tumor samples of 31 patients. KRAS mutation status in the serum and tumor samples was consistent in 44 of the 65 pairs (67.7{\%}). There was a significant correlation between the mutations detected in the serum sample and the mutations detected in the matched tumor sample (correlation index, 0.35; p <0.004). Twenty-two of the 57 patients (38.5{\%}) received anti-epidermal growth factor receptor therapy as any line therapy. There was no significant difference in the overall survival (OS) in accordance to the status of KRASmutations in both the serum and tumor samples (p > 0.05). In a multivariate analysis, liver metastasis and no cytoreductive operation were independent prognostic factors for decreased OS. Conclusion The serum sample might alternatively be used when it is difficult to obtain tumor tissues for analyzing the status of KRAS mutation in patients with advanced CRC.",
keywords = "KRAS, Mutation, Neoplasms, Serum",
author = "Kim, {Seung Tae} and Chang, {Won Jin} and Lihua Jin and Sung, {Jae Sook} and Choi, {Yoon Ji} and Kim, {Yeul Hong}",
year = "2015",
doi = "10.4143/crt.2014.106",
language = "English",
volume = "47",
pages = "796--803",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Society for Thoracic and Cardiovascular Surgery",
number = "4",

}

TY - JOUR

T1 - Can serum be used for analyzing the KRAS mutation status in patients with advanced colorectal cancer?

AU - Kim, Seung Tae

AU - Chang, Won Jin

AU - Jin, Lihua

AU - Sung, Jae Sook

AU - Choi, Yoon Ji

AU - Kim, Yeul Hong

PY - 2015

Y1 - 2015

N2 - Purpose KRAS mutations have been used widely as prognostic or predictive marker in patients with advanced colorectal cancer (CRC). However, it may be difficult to obtain a tumor tissue for analyzing the status of KRAS mutation in large proportion of patients with advanced disease. Materials and Methods We obtained pairs of tumor and serum samples from 65 patients with advanced CRC, between March 2008 and July 2011. KRAS mutation status from the tumor samples was analyzed by genomic polymerase chain reaction and direct sequence, and KRASmutation status from the serum samples was determined by a genomic polymerase chain reaction- restriction fragment length polymorphism assay. Results KRAS mutations were detected in the serum samples of 26 patients and in the tumor samples of 31 patients. KRAS mutation status in the serum and tumor samples was consistent in 44 of the 65 pairs (67.7%). There was a significant correlation between the mutations detected in the serum sample and the mutations detected in the matched tumor sample (correlation index, 0.35; p <0.004). Twenty-two of the 57 patients (38.5%) received anti-epidermal growth factor receptor therapy as any line therapy. There was no significant difference in the overall survival (OS) in accordance to the status of KRASmutations in both the serum and tumor samples (p > 0.05). In a multivariate analysis, liver metastasis and no cytoreductive operation were independent prognostic factors for decreased OS. Conclusion The serum sample might alternatively be used when it is difficult to obtain tumor tissues for analyzing the status of KRAS mutation in patients with advanced CRC.

AB - Purpose KRAS mutations have been used widely as prognostic or predictive marker in patients with advanced colorectal cancer (CRC). However, it may be difficult to obtain a tumor tissue for analyzing the status of KRAS mutation in large proportion of patients with advanced disease. Materials and Methods We obtained pairs of tumor and serum samples from 65 patients with advanced CRC, between March 2008 and July 2011. KRAS mutation status from the tumor samples was analyzed by genomic polymerase chain reaction and direct sequence, and KRASmutation status from the serum samples was determined by a genomic polymerase chain reaction- restriction fragment length polymorphism assay. Results KRAS mutations were detected in the serum samples of 26 patients and in the tumor samples of 31 patients. KRAS mutation status in the serum and tumor samples was consistent in 44 of the 65 pairs (67.7%). There was a significant correlation between the mutations detected in the serum sample and the mutations detected in the matched tumor sample (correlation index, 0.35; p <0.004). Twenty-two of the 57 patients (38.5%) received anti-epidermal growth factor receptor therapy as any line therapy. There was no significant difference in the overall survival (OS) in accordance to the status of KRASmutations in both the serum and tumor samples (p > 0.05). In a multivariate analysis, liver metastasis and no cytoreductive operation were independent prognostic factors for decreased OS. Conclusion The serum sample might alternatively be used when it is difficult to obtain tumor tissues for analyzing the status of KRAS mutation in patients with advanced CRC.

KW - KRAS

KW - Mutation

KW - Neoplasms

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=84946721234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946721234&partnerID=8YFLogxK

U2 - 10.4143/crt.2014.106

DO - 10.4143/crt.2014.106

M3 - Article

VL - 47

SP - 796

EP - 803

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 4

ER -